What is he best known for?
The fields of study Pieter Sonneveld is best known for:
- Cancer
- Chemotherapy
- Multiple myeloma
Pieter Sonneveld merges Internal medicine with Pediatrics in his research.
He performs integrative Pediatrics and Internal medicine research in his work.
Pieter Sonneveld connects Oncology with Cancer research in his study.
Borrowing concepts from Leukemia, he weaves in ideas under Cancer research.
His study deals with a combination of Leukemia and Myeloid leukemia.
His Myeloid leukemia study frequently links to related topics such as Immunology.
His Daunorubicin research extends to the thematically linked field of Immunology.
He performs multidisciplinary study on Chemotherapy and Bortezomib in his works.
Pieter Sonneveld performs multidisciplinary study on Multiple myeloma and Thalidomide in his works.
His most cited work include:
- International uniform response criteria for multiple myeloma (2267 citations)
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma (2171 citations)
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (643 citations)
What are the main themes of his work throughout his whole career to date
His work on Genetics as part of general Gene research is frequently linked to Cancer research, thereby connecting diverse disciplines of science.
He performs integrative study on Genetics and Gene in his works.
Pieter Sonneveld integrates Cancer research and Leukemia in his research.
His Internal medicine research includes a combination of various areas of study, such as Oncology, Surgery, Gastroenterology and Intensive care medicine.
Pieter Sonneveld merges many fields, such as Oncology and Chemotherapy, in his writings.
Pieter Sonneveld merges Surgery with Chemotherapy in his research.
He integrates Gastroenterology with Internal medicine in his study.
His Multiple myeloma study is within the categories of Bortezomib, Lenalidomide and Thalidomide.
Many of his studies on Immunology involve topics that are commonly interrelated, such as Leukemia.
Pieter Sonneveld most often published in these fields:
- Internal medicine (83.05%)
- Multiple myeloma (52.54%)
- Chemotherapy (42.37%)
What were the highlights of his more recent work (between 2016-2021)?
- Multiple myeloma (100.00%)
- Internal medicine (75.00%)
- Oncology (62.50%)
In recent works Pieter Sonneveld was focusing on the following fields of study:
Pieter Sonneveld is doing genetic studies as part of his Gene expression profiling and Gene signature and Gene expression investigations.
His Multiple myeloma study frequently draws connections to adjacent fields such as Immunology.
His research on Immunology often connects related topics like Multiple myeloma.
His Internal medicine study frequently draws connections to other fields, such as Obesity.
His Obesity study frequently intersects with other fields, such as Internal medicine.
He connects Oncology with Intensive care medicine in his research.
While working in this field, Pieter Sonneveld studies both Intensive care medicine and Oncology.
His Gene study frequently draws parallels with other fields, such as Regulator.
His Regulator study typically links adjacent topics like Gene.
Between 2016 and 2021, his most popular works were:
- Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† (197 citations)
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial (136 citations)
- Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma (40 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
